Adamas Pharmaceuticals Inc (NASDAQ:ADMS)’s share price reached a new 52-week low during mid-day trading on Thursday . The stock traded as low as $9.03 and last traded at $9.58, with a volume of 25498 shares traded. The stock had previously closed at $10.14.
ADMS has been the topic of several recent research reports. HC Wainwright set a $45.00 price target on Adamas Pharmaceuticals and gave the stock a “buy” rating in a research report on Monday, September 17th. ValuEngine lowered Adamas Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, August 28th. Mizuho restated a “buy” rating and set a $75.00 price target on shares of Adamas Pharmaceuticals in a research report on Friday, August 17th. Cowen set a $30.00 price target on Adamas Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, November 1st. Finally, Zacks Investment Research upgraded Adamas Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, November 6th. One research analyst has rated the stock with a sell rating, four have given a hold rating and seven have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $32.13.
The stock has a market capitalization of $273.63 million, a price-to-earnings ratio of -2.51 and a beta of 1.43. The company has a debt-to-equity ratio of 1.01, a current ratio of 8.95 and a quick ratio of 8.74.
In other Adamas Pharmaceuticals news, CEO Gregory T. Went acquired 3,850 shares of the business’s stock in a transaction dated Wednesday, November 7th. The shares were purchased at an average cost of $12.98 per share, for a total transaction of $49,973.00. Following the transaction, the chief executive officer now owns 182,610 shares in the company, valued at $2,370,277.80. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Alfred G. Merriweather sold 1,665 shares of Adamas Pharmaceuticals stock in a transaction that occurred on Friday, September 21st. The stock was sold at an average price of $19.18, for a total value of $31,934.70. Following the completion of the sale, the chief financial officer now owns 25,460 shares in the company, valued at $488,322.80. The disclosure for this sale can be found here. 24.60% of the stock is currently owned by company insiders.
Several hedge funds have recently modified their holdings of the company. Marshall Wace LLP bought a new stake in shares of Adamas Pharmaceuticals in the 3rd quarter worth approximately $4,316,000. Vanguard Group Inc. boosted its position in shares of Adamas Pharmaceuticals by 1.9% during the third quarter. Vanguard Group Inc. now owns 1,008,448 shares of the specialty pharmaceutical company’s stock valued at $20,189,000 after purchasing an additional 18,879 shares in the last quarter. Teachers Advisors LLC boosted its position in shares of Adamas Pharmaceuticals by 68.7% during the third quarter. Teachers Advisors LLC now owns 61,024 shares of the specialty pharmaceutical company’s stock valued at $1,222,000 after purchasing an additional 24,859 shares in the last quarter. Macquarie Group Ltd. boosted its position in shares of Adamas Pharmaceuticals by 36.2% during the third quarter. Macquarie Group Ltd. now owns 1,785,118 shares of the specialty pharmaceutical company’s stock valued at $35,738,000 after purchasing an additional 474,808 shares in the last quarter. Finally, MetLife Investment Advisors LLC boosted its position in shares of Adamas Pharmaceuticals by 55.2% during the third quarter. MetLife Investment Advisors LLC now owns 16,709 shares of the specialty pharmaceutical company’s stock valued at $335,000 after purchasing an additional 5,940 shares in the last quarter. Hedge funds and other institutional investors own 94.01% of the company’s stock.
About Adamas Pharmaceuticals (NASDAQ:ADMS)
Adamas Pharmaceuticals, Inc discovers, develops, and sells therapies for chronic neurologic disorders. The company's approved/commercial product is GOCOVRI, an amantadine therapy for the treatment of levodopa-induced dyskinesia in patients with Parkinson's disease. Its partnered approved/commercial products include Namzaric (memantine hydrochloride extended-release and donepezil hydrochloride) capsules; and Namenda XR (memantine hydrochloride) extended release capsules for the treatment of moderate to severe Alzheimer's disease.
Featured Story: Google Finance Portfolio Tips and Tricks
Receive News & Ratings for Adamas Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.